MJFF in the News

Ron Winslow writes about the Parkinson's Progression Markers Initiative plans for expansion into studying biomarkers associated with mutations of the LRRK2 and alpha-synuclein genes.

The Parkinson's Progression Markers Initiative published its first paper in JAMA Neurology and its findings caught the attention of USA Today reporter, Karen Weintraub.

CEO, Todd Sherer, PhD, is a featured guest blogger on Forbes.com, explaining how the Foundation is forging new models of scientific collaboration to speed cures, and how it's working sofar.

Genetic Engineering & Biotechnology News - The Michael J. Fox Foundation ranks first and is highlighted as a "beacon of efficiently" among 20 nonprofit disease foundations that "help keep research alive."

Michael graces the cover of AARP and talks about family, his new show, and his optimistic outlook on life with Parkinson's. The Foundation's Debi Brooks and Todd Sherer are also quoted in the article.

The Lancet recommends that the NIH Parkinson's Disease Biomarkers Program should aim to coordinate data collection methods with and validate findings from Foundation-led studies PPMI and BioFIND.

In an op-ed featured in the February issue of Nature Medicine, MJFF's CEO Todd Sherer, PhD, urges his peers in drug development to embrace the power of collaboration.

Forbes' Matthew Herper highlights Michael J. Fox's comments from the first annual Forbes Healthcare Summit where Michael and Debi Brook were featured panelists.